Course outline
Module 1
Module 1: Foundations of Psychedelic Pharmacology
Foundations of Psychedelic Pharmacology
Knowledge check
Q1. Which neurotransmitter receptor is the primary target of classic serotonergic psychedelics such as psilocybin and LSD?
- A. Dopamine D2 receptor
- B. 5-HT2A serotonin receptor ✓
- C. GABA-A receptor
- D. NMDA glutamate receptor
Why: Classic psychedelics like psilocin (the active metabolite of psilocybin) and LSD act as partial agonists at the 5-HT2A receptor, and activation of this receptor is considered central to their perceptual and cognitive effects.
Q2. What is psilocybin's relationship to its active form, psilocin?
- A. Psilocin is an inactive byproduct that is excreted unchanged
- B. Psilocybin is a prodrug that is dephosphorylated in the body to form psilocin ✓
- C. Psilocybin and psilocin are two unrelated compounds found in the same mushroom species
- D. Psilocin is a synthetic analogue that is converted into psilocybin in the liver
Why: Psilocybin is a phosphorylated prodrug. After ingestion, phosphatase enzymes remove the phosphate group, producing psilocin, which is the compound that binds to serotonin receptors.
Q3. Ketamine's antidepressant effects are thought to rely heavily on which mechanism?
- A. Full agonism at mu-opioid receptors
- B. Inhibition of monoamine oxidase across the brain
- C. Non-competitive antagonism of NMDA glutamate receptors ✓
- D. Selective blockade of serotonin reuptake transporters
Why: Ketamine is a non-competitive NMDA receptor antagonist. Its rapid antidepressant action is hypothesized to involve downstream glutamate surges and enhanced synaptic plasticity, distinguishing it from conventional antidepressants.
Q4. What does it mean for a psychedelic compound to be a 'partial agonist'?
- A. It binds to a receptor but produces no biological response at all
- B. It binds to a receptor and produces a response that is weaker than that of a full agonist ✓
- C. It only activates the receptor in the presence of a full agonist
- D. It binds to a different receptor than the one that its name suggests
Why: A partial agonist binds to and activates a receptor, but produces a submaximal response even at saturating concentrations compared with a full endogenous agonist like serotonin.
Q5. Why is the concept of 'set and setting' important in psychedelic research?
- A. It refers to the chemical purity and dosage standardization of psychedelic compounds
- B. It describes how a person's mindset and the physical and social environment shape the subjective experience and outcomes of a psychedelic session ✓
- C. It is a legal classification system used by regulatory agencies to schedule substances
- D. It is a pharmacokinetic measurement of how quickly a drug is absorbed and cleared
Why: Set (the person's expectations, mood, and psychological state) and setting (the physical and social environment) are recognized as major modulators of psychedelic experiences, and they are carefully controlled in clinical trial design.
Module 2
Module 2: Clinical Trial Design and Ethics
Clinical Trial Design and Ethics
Knowledge check
Q1. In a randomized controlled trial of a psychedelic-assisted therapy, what is the primary purpose of randomization?
- A. To ensure participants know which treatment they are receiving
- B. To distribute known and unknown confounding variables evenly across treatment groups ✓
- C. To select only participants with the most severe symptoms
- D. To shorten the duration of the trial
Why: Randomization reduces selection bias by distributing both measured and unmeasured confounders roughly equally between the treatment and control groups, so differences in outcomes can be more confidently attributed to the intervention.
Q2. Why are psychedelic clinical trials often described as difficult to blind?
- A. Psychedelics are legal in all countries, so participants know the drug
- B. The noticeable subjective effects of psychedelics make it easy for participants to guess whether they received the active drug or placebo ✓
- C. Blinding is not required by regulatory agencies for any trial
- D. Placebos cannot be manufactured for psychoactive compounds
Why: Psychedelics produce strong and recognizable perceptual and emotional effects, so participants (and often therapists) can usually tell active doses from placebo, compromising blinding and potentially inflating expectancy effects.
Q3. What is the purpose of an informed consent process in a psychedelic therapy trial?
- A. To transfer legal liability entirely to the participant
- B. To ensure participants understand risks, benefits, alternatives, and their right to withdraw before enrolling ✓
- C. To replace the need for a safety monitoring board
- D. To guarantee a positive outcome for the participant
Why: Informed consent protects autonomy by ensuring participants comprehend the study's risks (including psychological distress and adverse reactions), potential benefits, alternatives, and their right to withdraw at any time without penalty.
Q4. Which phase of clinical trials typically focuses primarily on safety, dosing, and tolerability in a small group of participants?
- A. Phase I ✓
- B. Phase II
- C. Phase III
- D. Phase IV
Why: Phase I trials are typically small and aim to establish safety, tolerability, pharmacokinetics, and appropriate dose ranges before testing efficacy in larger groups in later phases.
Q5. Why might a trial include a psychological preparation and integration component alongside the drug session?
- A. Because the drug itself has no therapeutic effect
- B. To support participant safety, help process experiences, and contribute to therapeutic outcomes ✓
- C. To extend the trial duration for billing purposes
- D. To eliminate the need for any monitoring during sessions
Why: Preparation and integration sessions help participants set expectations, manage challenging experiences, and translate insights into lasting change, while also contributing to safety and to the therapeutic model being studied.
Module 3
Module 3: Regulatory Pathways for Psychedelic Therapies
Regulatory Pathways for Psychedelic Therapies
Knowledge check
Q1. Which U.S. agency is primarily responsible for reviewing and approving new drugs, including psychedelic-assisted therapies, for safety and efficacy?
- A. The Drug Enforcement Administration (DEA)
- B. The Food and Drug Administration (FDA) ✓
- C. The National Institutes of Health (NIH)
- D. The Centers for Disease Control and Prevention (CDC)
Why: The FDA evaluates investigational new drug applications and new drug applications for safety and efficacy. The DEA handles scheduling and controlled substance enforcement, while the NIH funds research and the CDC focuses on disease prevention and surveillance.
Q2. What is the purpose of an Investigational New Drug (IND) application in the context of psychedelic research?
- A. To market a psychedelic drug to the public once it has been proven safe
- B. To allow a sponsor to legally administer an unapproved drug to human subjects in clinical trials ✓
- C. To request a change in a substance's federal scheduling status
- D. To obtain patent protection for a novel psychoactive compound
Why: An IND application gives the FDA's authorization for clinical investigation of an unapproved drug in humans. Without it, researchers generally cannot legally administer the substance to trial participants, even for research purposes.
Q3. Under the U.S. Controlled Substances Act, what does a Schedule I classification indicate?
- A. The substance has accepted medical use and low potential for abuse
- B. The substance has no currently accepted medical use and a high potential for abuse ✓
- C. The substance is approved for over-the-counter sale
- D. The substance is only regulated at the state level
Why: Schedule I substances are defined as having high abuse potential and no currently accepted medical use in the United States. Psilocybin and MDMA have historically been in this category, which is one reason researchers must obtain special DEA authorization to study them.
Q4. What is the typical sequence of clinical trial phases for a new therapeutic drug?
- A. Phase III, then Phase II, then Phase I, then market approval
- B. Phase I (safety), Phase II (efficacy and dosing), Phase III (large-scale confirmation), then regulatory review ✓
- C. Phase II, then Phase I, then Phase IV, then Phase III
- D. Phase I, then market approval, then Phase II and III
Why: Drug development generally proceeds from Phase I, which tests safety in small groups, to Phase II, which assesses efficacy and dose-finding, to Phase III, which confirms effectiveness in larger populations. Regulatory review follows successful completion, and Phase IV monitors the drug after approval.
Q5. Why does the FDA's Breakthrough Therapy designation matter for psychedelic-assisted therapy developers?
- A. It exempts the therapy from all safety monitoring requirements
- B. It grants automatic approval without clinical trials
- C. It is intended to expedite development and review for drugs showing substantial improvement over available treatments for serious conditions ✓
- D. It permanently removes the substance from federal controlled substance schedules
Why: Breakthrough Therapy designation is designed to speed development and review for serious conditions when preliminary evidence shows substantial improvement over existing options. It increases FDA guidance and interaction but does not waive the need for rigorous clinical evidence or remove scheduling restrictions.
Module 4
Module 4: Psychotherapy Integration and Set and Setting
Psychotherapy Integration and Set and Setting
Knowledge check
Q1. In psychedelic-assisted therapy, what does the term 'set' most accurately refer to?
- A. The physical room layout and lighting used during a session
- B. The participant's mindset, including expectations, mood, and psychological state going into the experience ✓
- C. The specific dose of the psychedelic compound administered
- D. The number of therapy sessions scheduled before and after the experience
Why: 'Set' refers to the internal psychological state of the person, including their expectations, emotional condition, intentions, and prior experiences. It is distinct from 'setting,' which refers to the external environment.
Q2. Which of the following best describes 'setting' in the context of psychedelic therapy?
- A. The participant's personal beliefs about the treatment
- B. The external physical and social environment in which the session takes place ✓
- C. The schedule of follow-up integration sessions
- D. The pharmacological profile of the substance used
Why: Setting encompasses the physical surroundings (room comfort, lighting, music, safety) and the social context (presence and demeanor of facilitators, whether the person feels supported). It shapes how the experience unfolds.
Q3. Why is psychotherapy integration considered important after a psychedelic experience?
- A. It is required by law in all jurisdictions where psychedelics are legal
- B. It helps participants make meaning of insights and translate them into lasting behavioral and emotional change ✓
- C. It extends the duration of the drug's pharmacological effects
- D. It replaces the need for any preparation before the session
Why: Integration sessions help participants process, interpret, and apply what emerged during the psychedelic experience to daily life. Without integration, insights may fade or remain unused, limiting therapeutic benefit.
Q4. Which practice is most consistent with best-practice guidance on preparing participants for psychedelic sessions?
- A. Withholding information about possible difficult experiences to avoid anxiety
- B. Conducting preparation sessions that establish rapport, clarify expectations, and address concerns about the experience ✓
- C. Encouraging participants to use the session to test unrelated substances
- D. Skipping preparation for experienced users to save time
Why: Thorough preparation builds trust, sets realistic expectations, reduces fear, and helps the participant articulate intentions. This strengthens the 'set' component and improves safety and therapeutic outcomes.
Q5. What is a potential risk if the 'setting' of a psychedelic session is poorly designed?
- A. The session will always produce positive long-term outcomes regardless of conditions
- B. Discomfort, feelings of insecurity, or heightened anxiety may increase the likelihood of a distressing experience ✓
- C. The dosage will automatically be reduced by the environment
- D. Integration sessions will no longer be necessary
Why: An unsafe or uncomfortable environment can amplify anxiety and fear, potentially leading to a difficult or traumatic experience. Careful attention to setting helps promote feelings of safety, comfort, and trust.
Module 5
Module 5: Neuroscience of Mental Health and Brain Imaging
Neuroscience of Mental Health and Brain Imaging
Knowledge check
Q1. Which brain imaging technique measures changes in blood oxygenation to infer neural activity?
- A. Electroencephalography (EEG)
- B. Functional magnetic resonance imaging (fMRI) ✓
- C. Positron emission tomography (PET) using a radioactive tracer for glucose
- D. Magnetoencephalography (MEG)
Why: fMRI detects the blood-oxygen-level-dependent (BOLD) signal, which reflects changes in oxygenated versus deoxygenated hemoglobin as neural activity alters local blood flow. EEG and MEG measure electrical or magnetic fields directly, and PET measures radiotracer uptake rather than blood oxygenation.
Q2. What is a neurotransmitter?
- A. A structural protein that forms the myelin sheath around axons
- B. A chemical messenger released at a synapse to signal another neuron or cell ✓
- C. A type of glial cell that supplies oxygen to neurons
- D. An electrical impulse that travels along the axon
Why: Neurotransmitters such as serotonin, dopamine, and glutamate are released from the presynaptic neuron and bind to receptors on the postsynaptic cell, transmitting signals across the synapse. Myelin, glia, and action potentials serve different roles.
Q3. Which neurotransmitter system is most directly associated with the mechanism of classic serotonergic psychedelics such as psilocybin and LSD?
- A. GABA
- B. Acetylcholine
- C. Serotonin, particularly the 5-HT2A receptor ✓
- D. Endogenous opioids
Why: Classic psychedelics act primarily as agonists at the serotonin 5-HT2A receptor, which is widely expressed in cortical regions involved in perception and cognition. This receptor action is considered central to their subjective and neural effects.
Q4. What does the term 'neuroplasticity' refer to?
- A. The brain's permanent loss of neurons with age
- B. The brain's ability to reorganize its structure and function in response to experience, learning, or injury ✓
- C. The fixed, genetically predetermined wiring of the adult brain
- D. The speed at which electrical signals travel along nerves
Why: Neuroplasticity describes the brain's capacity to modify synaptic connections, neural networks, and sometimes structure in response to experience. It is a key concept in research on how mental health treatments may produce lasting change.
Q5. Why is a placebo control important in neuroimaging studies of psychedelic-assisted therapy?
- A. It increases the strength of the BOLD signal in the scanner
- B. It helps separate the effects of the drug from expectancy, setting, and the therapeutic context ✓
- C. It is required to measure the drug's half-life in the blood
- D. It allows researchers to skip informed consent procedures
Why: Psychedelic experiences are strongly shaped by expectations, environment, and therapist interaction. A placebo control, often combined with blinding, helps researchers determine how much observed brain or symptom changes are attributable to the substance itself rather than to these non-pharmacological factors.
Module 6
Module 6: Research Careers in Academia and Industry
Research Careers in Academia and Industry
Knowledge check
Q1. Which of the following best describes a typical role for a postdoctoral researcher in an academic psychedelics research lab?
- A. Managing the university's finances and grant budgets
- B. Conducting independent research under a principal investigator while building publication records and skills for a future faculty or industry position ✓
- C. Serving as the final regulatory approver for clinical trial protocols
- D. Recruiting undergraduate students for administrative support only
Why: Postdoctoral positions are training appointments in which researchers conduct hands-on research, often under a principal investigator, to develop publication records and expertise needed for independent academic or industry careers.
Q2. In the context of clinical research, what does the abbreviation IRB stand for?
- A. International Research Budget
- B. Institutional Research Board
- C. Institutional Review Board ✓
- D. Integrated Research Brief
Why: An Institutional Review Board (IRB) is a committee that reviews and approves research involving human participants to protect their rights, safety, and welfare before a study can begin.
Q3. Which phase of clinical drug development typically focuses on assessing safety and dosing in a small group of healthy volunteers or patients?
- A. Phase I ✓
- B. Phase II
- C. Phase III
- D. Phase IV
Why: Phase I trials are the first stage of testing in humans and primarily evaluate safety, tolerability, and pharmacokinetics, usually in a small number of participants.
Q4. Which career path is most associated with working in the pharmaceutical or biotech industry rather than in a university setting?
- A. Tenure-track professor
- B. Clinical Research Associate (CRA) monitoring trial sites for a sponsor company ✓
- C. Graduate teaching assistant
- D. Departmental seminar coordinator
Why: Clinical Research Associates are commonly employed by sponsor companies or contract research organizations to oversee trial sites, making this an industry-focused role.
Q5. Why do researchers in psychedelic science often need to pursue interdisciplinary training?
- A. Because psychedelic research is entirely limited to laboratory chemistry
- B. Because the field combines pharmacology, neuroscience, psychiatry, psychology, ethics, and regulatory science ✓
- C. Because universities prohibit single-discipline researchers from publishing
- D. Because interdisciplinary training is required only for undergraduate students
Why: Psychedelic mental health research spans multiple domains, including pharmacology, neuroscience, clinical psychiatry, psychotherapy, ethics, and regulation, so interdisciplinary skills are highly valuable.
Module 7
Module 7: Harm Reduction, Policy, and Public Communication
Harm Reduction, Policy, and Public Communication
Knowledge check
Q1. Which of the following best describes the core goal of harm reduction in the context of psychedelic use?
- A. Preventing all drug use through strict legal penalties
- B. Minimizing health and safety risks for people who use substances, regardless of whether they stop using ✓
- C. Encouraging people to use psychedelics in unsupervised settings
- D. Limiting access to research so that fewer people are exposed to risk
Why: Harm reduction focuses on reducing the negative health and social consequences of drug use without requiring abstinence as a precondition. It meets people where they are and emphasizes practical safety measures.
Q2. Why is 'set and setting' a commonly cited principle in psychedelic harm reduction?
- A. It refers only to the chemical purity of the substance being used
- B. It emphasizes that a person's mindset and the physical and social environment strongly influence the psychedelic experience and its risks ✓
- C. It is a legal term used to determine whether a facility is licensed
- D. It describes the dosage schedule recommended by regulatory agencies
Why: The concept, popularized in psychedelic research, holds that mindset (set) and environment (setting) shape outcomes significantly. Attention to both is a practical way to reduce the likelihood of distressing experiences.
Q3. What is a key public communication challenge when discussing psychedelic research findings with the general public?
- A. Avoiding any mention of potential benefits to prevent public interest
- B. Conveying nuance, including both promising results and limitations or risks, without overstating or dismissing the evidence ✓
- C. Using only technical jargon so the public does not misinterpret results
- D. Waiting until all trials are fully completed before any communication
Why: Accurate science communication requires presenting preliminary findings with appropriate caveats, including sample size limits, study design, and potential risks. Overhyping or dismissing results can both distort public understanding and policy.
Q4. Which term describes the process by which a regulatory body evaluates a drug and decides whether it can be marketed for specific medical uses?
- A. Scheduling
- B. Decriminalization
- C. Approval (regulatory licensure) ✓
- D. Surveillance
Why: Regulatory approval, such as by the FDA in the US, is the formal process of reviewing safety and efficacy evidence before a drug can be marketed for a particular indication. Scheduling concerns legal control status, while decriminalization changes penalties for possession.
Q5. What does 'drug checking' or 'fentanyl test strips' primarily aim to address in harm reduction services?
- A. Determining the legal status of a substance
- B. Identifying unexpected or dangerous adulterants in a substance so users can make safer decisions ✓
- C. Measuring how long a substance stays in the body for employment screening
- D. Standardizing the potency of street drugs for pricing
Why: Drug checking services help people learn what is actually in their substances, including contaminants like fentanyl that may not be disclosed. This information allows people to adjust their behavior and reduce overdose risk.